Inflammatory breast cancer and development of brain metastases: risk factors and outcomes

Breast Cancer Research and Treatment

Volumn 151, Issue 1, 2015, Pages 225-232

  Warren, Laura E G ^a   Guo, Hao ^b   Regan, Meredith M ^b   Nakhlis, Faina ^c   Yeh, Eren D ^c   Jacene, Heather A ^c   Hirshfield Bartek, Judi ^c   Overmoyer, Beth A ^c   Bellon, Jennifer R ^c  

^a HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Brain metastases; Inflammatory breast cancer; Surveillance

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA; PROGESTERONE RECEPTOR;

ADULT; AGED; BRAIN NEOPLASMS; CANCER STAGING; FEMALE; GENETICS; HUMAN; INFLAMMATORY BREAST NEOPLASMS; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; RISK FACTOR; SECONDARY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; RISK FACTORS;

EID: 84937758854     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3381-8     Document Type: Article

References (38)

1. Lee YT (1983) Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol 23(3):175–180
2. Tsukada Y, Fouad A, Pickren JW, Lane WW (1983) Central nervous system metastasis from breast carcinoma Autopsy study. Cancer 52(12):2349–2354
3. Patanaphan V, Salazar OM, Risco R (1988) Breast cancer: metastatic patterns and their prognosis. South Med J 81(9):1109–1112
4. Kennecke H, Yerushalmi R, Woods R, Cheang MCU, Voduc D, Speers CH et al (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28(20):3271–3277
5. Leyland-Jones B (2009) Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 27(31):5278–5286
6. Boogerd W, Vos VW, Hart AA, Baris G (1993) Brain metastases in breast cancer; natural history, prognostic factors and outcome. J Neurooncol 15(2):165–174
7. Arvold ND, Oh KS, Niemierko A, Taghian AG, Lin NU, Abi-Raad RF et al (2012) Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. Breast Cancer Res Treat 136(1):153–160
8. Stemmler H-J, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V (2007) Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 18(1):23–28
9. Nguyen DX, Bos PD, Massagué J (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9(4):274–284
10. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W (2008) A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70(2):510–514
11. Nieder C, Marienhagen K, Geinitz H, Molls M (2009) Validation of the graded prognostic assessment index for patients with brain metastases. Acta Oncol 48(3):457–459
12. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T et al (1997) Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37(4):745–751
13. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322(8):494–500
14. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ et al (1998) Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280(17):1485–1489
15. Horton J, Baxter DH, Olson KB (1971) The management of metastases to the brain by irradiation and corticosteroids. Am J Roentgenol Radium Ther Nucl Med 111(2):334–336
16. Niwińska A, Tacikowska M, Murawska M (2010) The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death. Int J Radiat Oncol Biol Phys 77(4):1134–1139
17. Miller KD, Weathers T, Haney LG, Timmerman R, Dickler M, Shen J et al (2003) Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 14(7):1072–1077
18. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer [Internet]. 2014. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 1 March 2015
19. Cristofanilli M, Valero V, Buzdar AU, Kau S-W, Broglio KR, Gonzalez-Angulo AM et al (2007) Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer 110(7):1436–1444
20. Anderson BWF, Chu KC, Chang S (2003) Inflammatory breast carcinoma and noninflammatory Locally advanced breast carcinoma: distinct clinicopathologic entities? J Clin Oncol 21(12):2254–2259
21. Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD (1998) Inflammatory breast carcinoma incidence and survival the surveillance, epidemiology, and end results program of the National Cancer. Cancer 82(12):2366–2372
22. Lentzsch S, Reichardt P, Weber F, Budach V, Dörken B (1999) Brain metastases in breast cancer: prognostic factors and management. Eur J Cancer 35(4):580–585
23. Gonzalez-Angulo AM, Cristofanilli M, Strom EA, Buzdar AU, Kau S-W, Broglio KR et al (2004) Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer 101(8):1760–1766
24. Dawood S, Ueno NT, Valero V, Andreopoulou E, Hsu L, Lara J et al (2010) Incidence of and survival following brain metastases among women with inflammatory breast cancer. Ann Oncol 22(3):2348–2355
25. Edge SB, Byrd, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, Trotti A (eds) (2011) American Joint Committee on Cancer Staging Manual, 7th edn. Springer, Chicago
26. Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA et al (2011) International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 22(3):515–523
27. Gray R (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154
28. Choudhury JB (2002) Non-parametric confidence interval estimation for competing risks analysis: application to contraceptive data. Stat Med 21(8):1129–1144
29. Scrucca L, Santucci A, Aversa F (2007) Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 40(4):381–387
30. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53(282):457–481
31. Greenwood M (1926) The errors of sampling of the survivorship tables. Rep Public Heal Stat Subj 33(1):26
32. DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR (1979) The natural history of breast cancer patients with brain metastases. Cancer 44(5):1913–1918
33. Altundag K, Bondy ML, Mirza NQ, Kau S-W, Broglio K, Hortobagyi GN et al (2007) Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer 110(12):2640–2647
34. Zimm S, Wampler GL, Stablein D, Hazra T, Young HF (1981) Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 48(2):384–394
35. Tsao M, Xu W, Sahgal A (2012) A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases. Cancer 118(9):2486–2493
36. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG et al (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 10(11):1037–1044
37. Halasz LM, Weeks JC, Neville BA, Taback N, Punglia RS (2013) Use of stereotactic radiosurgery for brain metastases from non-small cell lung cancer in the United States. Int J Radiat Oncol Biol Phys 85(2):e109–e116
38. Guadagnolo BA, Huo J, Liao K-P, Buchholz TA, Das P (2013) Changing trends in radiation therapy technologies in the last year of life for patients diagnosed with metastatic cancer in the United States. Cancer 119(5):1089–1097